197 related articles for article (PubMed ID: 31012504)
1. Long-term in vitro treatment with telomerase inhibitor MST-312 induces resistance by selecting long telomeres cells.
Morais KDS; Arcanjo DDS; de Faria Lopes GP; da Silva GG; da Mota THA; Gabriel TR; Rabello Ramos DDA; Silva FP; de Oliveira DM
Cell Biochem Funct; 2019 Jun; 37(4):273-280. PubMed ID: 31012504
[TBL] [Abstract][Full Text] [Related]
2. MST-312 Alters Telomere Dynamics, Gene Expression Profiles and Growth in Human Breast Cancer Cells.
Gurung RL; Lim SN; Low GK; Hande MP
J Nutrigenet Nutrigenomics; 2014; 7(4-6):283-98. PubMed ID: 26022559
[TBL] [Abstract][Full Text] [Related]
3. Effects of in vitro short- and long-term treatment with telomerase inhibitor in U-251 glioma cells.
Andrade da Mota TH; Reis Guimarães AF; Silva de Carvalho AÉ; Saldanha-de Araujo F; Pinto de Faria Lopes G; Pittella-Silva F; do Amaral Rabello D; Madureira de Oliveira D
Tumour Biol; 2021; 43(1):327-340. PubMed ID: 34957975
[TBL] [Abstract][Full Text] [Related]
4. Long-term exposure to MST-312 leads to telomerase reverse transcriptase overexpression in MCF-7 breast cancer cells.
Morais KS; Guimarãesb AFR; Ramos DAR; Silva FP; de Oliveira DM
Anticancer Drugs; 2017 Aug; 28(7):750-756. PubMed ID: 28520570
[TBL] [Abstract][Full Text] [Related]
5. Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.
Frink RE; Peyton M; Schiller JH; Gazdar AF; Shay JW; Minna JD
Oncotarget; 2016 May; 7(22):31639-51. PubMed ID: 27192120
[TBL] [Abstract][Full Text] [Related]
6. Agents that target telomerase and telomeres.
Raymond E; Sun D; Chen SF; Windle B; Von Hoff DD
Curr Opin Biotechnol; 1996 Dec; 7(6):583-91. PubMed ID: 8939642
[TBL] [Abstract][Full Text] [Related]
7. Consequences of telomerase inhibition by BIBR1532 on proliferation and chemosensitivity of chondrosarcoma cell lines.
Parsch D; Brassat U; Brümmendorf TH; Fellenberg J
Cancer Invest; 2008 Jul; 26(6):590-6. PubMed ID: 18584350
[TBL] [Abstract][Full Text] [Related]
8. [Inhibition of telomeres and telomerase. Seeking for new anticancer drugs].
Raymond E; Faivre S; Dieras V; Von Hoff D
Bull Cancer; 1997 Dec; 84(12):1123-33. PubMed ID: 9587365
[TBL] [Abstract][Full Text] [Related]
9. Twisted epithelial-to-mesenchymal transition promotes progression of surviving bladder cancer T24 cells with hTERT-dysfunction.
Xue Y; Li L; Zhang D; Wu K; Chen Y; Zeng J; Wang X; He D
PLoS One; 2011; 6(11):e27748. PubMed ID: 22110753
[TBL] [Abstract][Full Text] [Related]
10. [The role of alternative lengthening of telomeres mechanisms in carcinogenesis and prospects for using an anti-telomerase drugs in malignant tumors treatment].
Grach AA
Tsitologiia; 2011; 53(10):759-71. PubMed ID: 22232932
[TBL] [Abstract][Full Text] [Related]
11. Targeting DNA-PKcs and telomerase in brain tumour cells.
Gurung RL; Lim HK; Venkatesan S; Lee PS; Hande MP
Mol Cancer; 2014 Oct; 13():232. PubMed ID: 25307264
[TBL] [Abstract][Full Text] [Related]
12. Anticancer therapy targeting telomeres and telomerase : current status.
Parkinson EK; Minty F
BioDrugs; 2007; 21(6):375-85. PubMed ID: 18020621
[TBL] [Abstract][Full Text] [Related]
13. Targeting telomerase with radiolabeled inhibitors.
Waghorn PA; Jackson MR; Gouverneur V; Vallis KA
Eur J Med Chem; 2017 Jan; 125():117-129. PubMed ID: 27657809
[TBL] [Abstract][Full Text] [Related]
14. Acquired cellular resistance to flavopiridol in a human colon carcinoma cell line involves up-regulation of the telomerase catalytic subunit and telomere elongation. Sensitivity of resistant cells to combination treatment with a telomerase inhibitor.
Incles CM; Schultes CM; Kelland LR; Neidle S
Mol Pharmacol; 2003 Nov; 64(5):1101-8. PubMed ID: 14573759
[TBL] [Abstract][Full Text] [Related]
15. Effects of rapamycin on the mechanistic target of rapamycin (mTOR) pathway and telomerase in breast cancer cells.
Gopalakrishnan K; Venkatesan S; Low ESH; Hande MP
Mutat Res Genet Toxicol Environ Mutagen; 2018 Dec; 836(Pt B):103-113. PubMed ID: 30442335
[TBL] [Abstract][Full Text] [Related]
16. Alternative lengthening of telomeres is induced by telomerase inhibitors in Barrett's esophageal cells.
Qin X; Qi B; Zhao B
Oncol Rep; 2013 Apr; 29(4):1399-404. PubMed ID: 23338150
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of the G-quadruplex-stabilizing telomerase inhibitor 3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (RHPS4) in vitro: activity in human tumor cells correlates with telomere length and can be enhanced, or antagonized, with cytotoxic agents.
Cookson JC; Dai F; Smith V; Heald RA; Laughton CA; Stevens MF; Burger AM
Mol Pharmacol; 2005 Dec; 68(6):1551-8. PubMed ID: 16150933
[TBL] [Abstract][Full Text] [Related]
18. A human breast cancer model for the study of telomerase inhibitors based on a new biotinylated-primer extension assay.
Raymond E; Sun D; Izbicka E; Mangold G; Silvas E; Windle B; Sharma S; Soda H; Laurence R; Davidson K; Von Hoff DD
Br J Cancer; 1999 Jul; 80(9):1332-41. PubMed ID: 10424733
[TBL] [Abstract][Full Text] [Related]
19. Cell-based chemical fingerprinting identifies telomeres and lamin A as modifiers of DNA damage response in cancer cells.
Fujiwara C; Muramatsu Y; Nishii M; Tokunaka K; Tahara H; Ueno M; Yamori T; Sugimoto Y; Seimiya H
Sci Rep; 2018 Oct; 8(1):14827. PubMed ID: 30287851
[TBL] [Abstract][Full Text] [Related]
20. Long-term cultivation of colorectal carcinoma cells with anti-cancer drugs induces drug resistance and telomere elongation: an in vitro study.
Kuranaga N; Shinomiya N; Mochizuki H
BMC Cancer; 2001; 1():10. PubMed ID: 11518543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
